Redesigning the map of uremic toxins

Contributions to Nephrology

Volumn 133, Issue , 2001, Pages 42-70

  Vanholder, R ^a   De Smet, R ^a   Lameire, N H ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TOXIN; UREMIA MIDDLE MOLECULE TOXINS;

CHEMISTRY; HUMAN; METABOLISM; MOLECULAR WEIGHT; OSMOLARITY; REVIEW; SOLUTION AND SOLUBILITY; TECHNIQUE; UREMIA;

HUMANS; METHODS; MOLECULAR WEIGHT; OSMOLAR CONCENTRATION; SOLUTIONS; TOXINS, BIOLOGICAL; UREMIA;

EID: 0035534289     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000060114     Document Type: Article

References (201)

1. Vanholder R, De Smet R: Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999;10:1815-1823.
2. Vanholder R, De Smet R, Hsu C, Vogeleere P, Ringoir S: Uremic toxicity: The middle molecule hypothesis revisited. Semin Nephrol 1994;14:205-218.
3. Vanholder RC, Ringoir SM: Adequacy of dialysis: A critical analysis (editorial). Kidney Int 1992;42:540-558.
4. Leypoldt JK, Cheung AK, Carroll CE et al: Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 1999;33:349-355.
5. Anderstam B, Mamoun AH, Sodersten P, Bergstrom J: Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat. J Am Soc Nephrol 1996;7:2453-2460.
6. Mamoun AH, Sodersten P, Anderstam B, Bergstrom J: Evidence of splanchnic-brain signaling in inhibition of ingestive behavior by middle molecules. J Am Soc Nephrol 1999;10:309-314.
7. Kamanna VS, Kashyap ML, Pai R et al: Uremic serum subfraction inhibits apolipoprotein: A-I production by a human hepatoma cell line. J Am Soc Nephrol 1994;5:193-200.
8. Stabellini G, Mariani G, Pezzetti F, Calastrini C: Direct inhibitory effect of uremic toxins and polyamines on proliferation of VERO culture cells. Exp Mol Pathol 1997;64:147-155.
9. Severini G, Diana L, Di Giovannandrea R, Sagliaschi G: Influence of uremic middle molecules on in vitro stimulated lymphocytes and interleukin-2 production. ASAIO J 1996;42:64-67.
10. Hornberger JC, Chernew M, Petersen J, Garber AM: A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992;3:1227-1237.
11. Hakim RM, Held PJ, Stannard DC et al: Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996;50:566-570.
12. Chandran PK, Liggett R, Kirkpatrick B: Patient survival on PAN/AN69 membrane hemodialysis: A ten-year analysis. J Am Soc Nephrol 1993;4:1199-1204.
13. Bloembergen WE, Hakim RM, Stannard DC et al: Relationship of dialysis membrane and cause-specific mortality. Am J Kidney Dis 1999;33:1-10.
14. Hartmann J, Fricke H, Schiffl H: Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997;30:366-373.
15. Blankestijn PJ, Vos PF, Rabelink TJ et al: High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995;5:1703-1708.
16. Malberti F, Surian M, Farina M et al: Effect of hemodialysis and hemodiafiltration on uremic neuropathy. Blood Purif 1991;9:285-295.
17. Locatelli F, Marcelli D, Conte F et al: Comparison of mortality in ESRD patients on convective and diffuse extracorporeal treatments. The Registro Lombardo Dialisi e Trapianto. Kidney Int 1999;55: 286-293.
18. Dellanna F, Wuepper A, Baldamus CA: Internal filtration - Advantage in haemodialysis? Nephrol Dial Transplant 1996;11(suppl 2):83-86.
19. Maduell F, del Pozo C, Garcia H et al: Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 1999;14:1202-1207.
20. Kessler M, Netter P, Azoulay E et al: Dialysis-associated arthropathy: A multicentre survey of 171 patients receiving haemodialysis for over 10 years. The Co-Operative Group on Dialysis-Associated Arthropathy. Br J Rheumatol 1992;31:157-162.
21. Jadoul M, Garbar C, Vanholder R et al: Prevalence of histological beta-2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. Kidney Int 1998;54:956-959.
22. Jadoul M, Garbar C, Noel H et al: Histological prevalence of beta-2-microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. Kidney Int 1997;51:1928-1932.
23. Niwa T, Sato M, Katsuzaki T et al: Amyloid beta-2-microglobulin is modified with N-epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int 1996;50:1303-1309.
24. Miyata T, Inagi R, Iida Y et al: Involvement of beta-2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994;93:521-528.
25. Canaud B, Assounga A, Kerr P, Aznar R, Mion C: Failure of a daily haemofiltration programme using a highly permeable membrane to return beta-2-microglobulin concentrations to normal in haemodialysis patients. Nephrol Dial Transplant 1992;7:924-930.
26. Locatelli F, Mastrangelo F, Redaelli B et al: Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996;50:1293-1302.
27. Koda Y, Nishi S, Miyazaki S et al: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997;52:1096-1101.
28. Chanard J, Bindi P, Lavaud S et al: Carpal tunnel syndrome and type of dialysis membrane. BMJ 1989;298:867-868.
29. Van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J: Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 1991;39:1012-1019.
30. Schwalbe S, Holzhauer M, Schaeffer J et al: Beta-2-microglobulin associated amyloidosis: A vanishing complication of long-term hemodialysis? Kidney Int 1997;52:1077-1083.
31. Assounga A, Canaud B, Vlavier JL et al: What does circulating beta-2-microglobulin signify in uremic patients on maintenance dialysis? Nephrologie 1987;8:301-306.
32. Mourad G, Argiles A: Renal transplantation relieves the symptoms but does not reverse beta-2-microglobulin amyloidosis. J Am Soc Nephrol 1996;7:798-804.
33. Amann K, Ritz E, Wiest G, Klaus G, Mall G: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994;4:1814-1819.
34. Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993;328:171-175.
35. Massry SG, Smogorzewski M: Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 1994;14:219-231.
36. Ramirez JA, Goodman WG, Belin TR et al: Calcitriol therapy and calcium-regulated PTH secretion in patients with secondary hyperparathyroidism. Am J Physiol 1994;267:E961-E967.
37. Patel SR, Ke HQ, Vanholder R, Koenig RJ, Hsu CH: Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest 1995;96:50-59.
38. D'Amour P, Jobin J, Hamel L, L'Ecuyer N: iPTH values during hemodialysis: Role of ionized Ca, dialysis membranes and iPTH assays. Kidney Int 1990;38:308-314.
39. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation and products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
40. Papanastasiou P, Grass L, Rodela H et al: Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994;46:216-222.
41. Friedlander MA, Witko-Sarsat V, Nguyen AT et al: The advanced glycation end-product pentosidineand monocyte activation in uremia. Clin Nephrol 1996;45:379-382.
42. Imani F, Horii Y, Suthanthiran M et al: Advanced glycosylation end-product-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon-gamma: Role in tissue remodeling. J Exp Med 1993;178:2165-2172.
43. Miyata T, Oda O, Inagi R et al: Beta-2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993;92:1243-1252.
44. Sakata S, Takahashi M, Kushida K et al: The relationship between pentosidine and hemodialysis-related connective tissue disorders. Nephron 1998;78:260-265.
45. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87: 432-438.
46. Witko-Sarsat V, Friedlander M, Nguyen KT et al: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161: 2524-2532.
47. Li YM, Tan AX, Vlassara H: Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1995;1:1057-1061.
48. Koschinsky T, He CJ, Mitsuhashi T et al: Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997;94:6474-6479.
49. Henle T, Deppisch R, Beck W et al: Advanced glycated end-products (AGE) during haemodialysis treatment: Discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999;14:1968-1975.
50. Miyata T, Ueda Y, Shinzato T et al: Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996;7:1198-1206.
51. Miyata T, Ueda Y, Horie K et al: Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney Int 1998;53:416-422.
52. Gugliucci A, Bendayan M: Renal fate of circulating advanced glycated end products (AGE): Evidence for reabsorption and catabolism of AGE peptides by renal proximal tubular cells. Diabetologia 1996;39:149-160.
53. Monnier VM, Sell DR, Nagaraj RH et al: Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 1992;41(suppl 2):36-41.
54. Miyata T, Wada Y, Cai Z et al: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997;51:1170-1181.
55. Makita Z, Bucala R, Rayfield EJ et al: Reactive glycosylation end products in diabetic uraemia and treatment of renal failure. Lancet 1994;343:1519-1522.
56. Fishbane S, Bucala R, Pereira BJ, Founds H, Vlassare H: Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney Int 1997;52:1645-1650.
57. Jadoul M, Ueda Y, Yasuda Y et al: Influence of hemodialysis membrane type on pentosidine plasma level, a marker of 'carbonyl stress'. Kidney Int 1999;55:2487-2492.
58. Hricik DE, Wu YC, Schulak A, Friedlander MA: Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. Clin Transplant 1996;10:568-573.
59. Hörl WH, Haag-Weber M, Georgopoulos A, Block LH: Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci USA 1990;87:6353-6357.
60. Haag-Weber M, Mai B, Hörl WH: Isolation of a granulocyte inhibitory protein from uraemic patients with homology of beta-2-microglobulin. Nephrol Dial Transplant 1994;9:382-388.
61. Haag-Weber M, Mai B, Hörl WH: Impaired cellular host defence in peritoneal dialysis by two granulocyte inhibitory proteins. Nephrol Dial Transplant 1994;9:1769-1773.
62. Tschesche H, Kopp C, Hörl WH, Hempelmann U: Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. J Biol Chem 1994;269:30274-30280.
63. Cohen G, Rudnicki M, Hörl WH: Isolation of modified ubiquitin as a neutrophil chemotaxis inhibitor from uremic patients. J Am Soc Nephrol 1998;9:451-456.
64. Hegbrant J, Thysell H, Ekman R: Elevated plasma level of opioid peptides and delta sleep-inducing peptide but not of corticotropin-releasing hormone in patients receiving chronic hemodialysis. Blood Purif 1991;9:188-194.
65. Letizia C, Mazzaferro S, De Ciocchis A et al: Effects of haemodialysis session on plasma beta-endorphin, ACTH and cortisol in patients with end-stage renal disease. Scand J Urol Nephrol 1996;30:399-402.
66. Bald M, Gerigk M, Rascher W: Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure. Am J Kidney Dis 1997;30:23-27.
67. Hegbrant J, Thysell H, Ekman R: Circulating neuropeptide Y in plasma from uremic patients consists of multiple peptide fragments. Peptides 1995;16:395-397.
68. Bischoff A, Avramidis P, Erdbrugger W, Munter K, Michel MC: Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y. Br J Pharmacol 1997;120:1335-1343.
69. Aguilera A, Codoceo R, Selgas R, et al: Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis patients: Their relationship with nutritional parameters. Nephrol Dial Transplant 1998;13:1476-1483.
70. Ishimitsu T, Nishikimi T, Saito Y et al: Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994;94:2158-2161.
71. Ikeda U, Kanbe T, Shimada K: Adrenomedullin increases inducible nitric oxide synthase in rat vascular smooth muscle cells stimulated with interleukin-1. Hypertension 1996;27:1240-1244.
72. Kabanda A, Jadoul M, Pochet JM et al: Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int 1994;45:1689-1696.
73. Cimerman N, Prebanda MT, Turk B et al: Interaction of cystatin C variants with papain and human cathepsins B, H and L. J Enzyme Inhib 1999;14:167-174.
74. 2-inhibitory protein. J Clin Invest 1993;92: 2099-2109.
75. Pelleymounter MA, Cullen MJ, Baker MB et al: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-543.
76. Halaas JL, Gajiwala KS, Maffei M et al: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-546.
77. Sharma K, Considine RV, Michael B et al: Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997;51:1980-1985.
78. Fontan MP, Rodriguez-Carmona A, Cordido F, Garcia-Buela J: Hyperleptinemia in uremic patients undergoing conservative management, peritoneal dialysis, and hemodialysis: A comparative analysis. Am J Kidney Dis 1999;34:824-831.
79. Young GA, Woodrow G, Kendall S et al: Increased plasma leptin/fat ratio in patients with chronic renal failure: A cause of malnutrition? Nephrol Dial Transplant 1997;12:2318-2323.
80. Johansen KL, Mulligan K, Tai V, Schambelan M: Leptin, body composition, and indices of malnutrition in patients on dialysis. Am J Soc Nephrol 1998;9:1080-1084.
81. Heumburger O, Lonnqvist F, Danielsson A, Nordenstrom J, Stenvinkel P: Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997;8:1423-1430.
82. Stenvinkel P, Lindholm B, Lonnqvist F, Katzarski K, Heimburger O: Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000;11:1303-1309.
83. Nishikawa M, Takagi T, Yoshikawa N et al: Measurement of serum leptin in patients with chronic renal failure on hemodialysis. Clin Nephrol 1999;51:296-303.
84. Odamaki M, Furuya R, Yoneyama T et al: Association of the serum leptin concentration with weight loss in chronic hemodialysis patients. Am J Kidney Dis 1999;33:361-368.
85. Bazilinski N, Dunea G: Peptidic uremic retention products (editorial). Int J Artif Organs 1991;14: 619-621.
86. Pascual M, Schifferli JA: Adsorption of complement factor D by polyacrylonitrile dialysis membranes. Kidney Int 1993;43:903-911.
87. Pascual M, Steiger G, Estreicher J et al: Metabolism of complement factor D in renal failure. Kidney Int 1998;34:529-536.
88. Volanakis JE, Barnum SR, Giddens M, Galla JH: Renal filtration and catabolism of complement protein D. N Engl J Med 1985;312:395-399.
89. Strobel WM, Gurke T, Schifferli JA: Lowering plasma levels of complement factor D with AN69 dialysis membranes. J Clin Apheresis 1999;14:188-189.
90. McLeish KR, Klein JB, Lederer ED, Head KZ, Ward RA: Azotemia, TNF-alpha, and LPS prime the human neutrophil oxidative burst by distinct mechanisms. Kidney Int 1996;50:407-416.
91. Dean RT, Wolff SP, McElligott MA: Histidine and proline are important sites of free radical damage to proteins. Free Radie Res Commun 1989;7:97-103.
92. Nguyen-Khoa T, Massy ZA, Witko-Sarsat V et al: Critical evaluation of plasma and LDL oxidant-trapping potential in hemodialysis patients. Kidney Int 1999;56:747-753.
93. Sarnatskaya VV, Ivanov AI, Nikolaev VG et al: Structure and binding properties of serum albumin in uremic patients at different periods of hemodialysis. Artif Organs 1998;22:107-115.
94. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
95. De Graaf J, Hak-Lemmers HL, Hectors MP et al: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991;11: 298-306.
96. Maggi E, Bellazzi R, Falaschi F et al: Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 1994;45:876-883.
97. Maggi E, Bellazi R, Gazo A, Seccia M, Bellomo G: Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994;46:869-876.
98. Roselaar SE, Nazhat NB, Winyard PG et al: Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 1995;48:199-206.
99. Daschner M, Lenhartz H, Botticher D et al: Influence of dialysis on plasma lipid peroxidation products and antioxidant levels. Kidney Int 1996;50:1268-1272.
100. Lesaffer G, De Smet R, Lameire N et al: Intradialytic removal of protein-bound uraemic toxins: Role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000;15:50-57.
101. Gulyassy PF: Can dialysis remove protein-bound toxins that accumulate because of renal secretory failure? ASAIO J 1994;40:92-94.
102. Vanholder R, Van Landschoot N, De Smet R, Schools A, Ringoir S: Drug protein binding in chronic renal failure: Evaluation of nine drugs. Kidney Int 1988;33:996-1004.
103. Depner TA: Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia. Kidney Int 1981;20:511-518.
104. Lim CF, Bernard BF, de Jong M et al: A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 1993;76:318-324.
105. Niwa T, Ise M: Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994;124:96-104.
106. Vanholder RC, De Smet RV, Ringoir SM: Assessment of urea and other uremic markers for quantification of dialysis efficacy. Clin Chem 1992;38:1429-1436.
107. Niwa T, Takeda N, Tatematsu A, Maeda K: Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem 1988;34:2264-2267.
108. Niwa T, Yazawa T, Kodama T et al: Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 1990;56:241-245.
109. Boumendil-Podevin EF, Podevin RA, Richet G: Uricosuric agents in uremic sera. Identification of indoxyl sulfata and hippuric acid. J Clin Invest 1975;55:1142-1152.
110. Porter RD, Cathcart-Rake WF, Wan SH, Whittier FC, Grantham JJ: Secretory activity and aryl acid content of serum, urine, and cerebrospinal fluid in normal and uremic man. J Lab Clin Med 1975;85:723-731.
111. McNamara PJ, Lalka D, Gibaldi M: Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 1981;98:730-740.
112. Gulyassy PF, Bottini AT, Stanfel LA, Jarrard EA, Depner TA: Isolation and chemical identification of inhibitors of plasma ligand binding. Kidney Int 1986;30:391-398.
113. De Smet R, Vogeleere P, van Kaer J, Lameire N, Vanholder R: Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients. J Chromatogr A 1999;847:141-153.
114. Dzúric R, Spustova V, Gerykova M: Pathogenesis and consequences of the alteration of glucose metabolism in renal insufficiency. Adv Exp Med Biol 1987;223:105-109.
115. Farrell PC, Gotch FA, Peters JH, Berridge BJ Jr, Lam M: Binding of hippurate in normal plasma and in uremic plasma pre- and postdialysis. Nephron 1987;20:40-46.
116. Thompson DC, Perera K, Fisher R, Brendel K: Cresol isomers: Comparison of toxic potency in rat liver slices. Toxicol Appl Pharmacol 1994;125:51-58.
117. Goodhart PJ, DeWolf WE Jr, Kruse LI: Mechanism-based inactivation of dopamine beta-hydroxylase by p-cresol and related alkylphenols. Biochemistry 1987;26:2576-2583.
118. Lascelles PT, Taylor WH: The effect upon tissue respiration in vitro of metabolites which accumulate in uraemic coma. Clin Sci 1966;31:403-413.
119. Yokoyama MT, Tabori C, Miller ER, Hogberg MG: The effects of antibiotics in the weanling pig diet on growth and the excretion of volatile phenolic and aromatic bacterial metabolites. Am J Clin Nutr 1982;35:1417-1424.
120. Heipieper HJ, Keweloh H, Rehm HJ: Influence of phenols on growth and membrane permeability of free and immobolized Escherichia coli. Appl Environ Microbiol 1991;57:1213-1217.
121. Vanholder R, De Smet R, Waterloos MA et al: Mechanisms of uremic inhibition of phagocyte-reactive species production: Characterization of the role of p-cresol. Kidney Int 1995;47:510-517.
122. Abreo K, Sella M, Gautreaux S et al: p-Cresol, a uremic compound, enhances the uptake of aluminum in hepatocytes. J Am Soc Nephrol 1997;8:935-942.
123. Wratten ML, Tetta C, De Smet R et al: Uremic ultrafiltrate inhibits platelet-activating factor synthesis. Blood Purif 1999;17:134-141.
124. De Kimpe J, Cornelis R, Vanholder R: In vitro methylation of arsenite by rabbit liver cytosol: Effect of metal ions, metal chelating agents, methyltransferase inhibitors and uremic toxins. Drug Chem Toxicol 1999;22:613-628.
125. De Smet R, Glorieux G, Hsu C, Vanholder R: p-Cresol and uric acid: Two old uremic toxins revisited. Kidney Int 1997;52(suppl 62):S8-S11.
126. Anderson IB, Mullen WH, Meeker JE et al: Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med 1996;124:726-734.
127. Niwa T, Ise M, Miyazaki T, Meada K: Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. Nephron 1993;65:82-87.
128. Takamura N, Maruyama T, Otagiri M: Effects of uremic toxins and fatty acids on serum protein binding of furosemide: Possible mechanism of the binding defect in uremia. Clin Chem 1997;43: 2274-2280.
129. Tsutsumi Y, Maruyama T, Takadate A, Shimada H, Otagiri M: Decreased bilirubin-bindingcapacity in uremic serum caused by an accumulation of furan dicarboxylic acid. Nephron 2000;85:60-64.
130. Sato M, Koyama M, Miyazaki T, Niwa T: Reduced renal clearance of furancarboxylic acid, a major albumin-bound organic acid, in undialyzed uremic patients. Nephron 1996;74:419-421.
131. Henderson SJ, Lindup WE: Renal organic acid transport: Uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia. J Pharmacol Exp Ther 1992;263:54-60.
132. Costigan MG, Lindup WE: Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia. Kidney Int 1996;49:634-638.
133. Mabuchi H, Nakahashi H: Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum. Nephron 1988;49:281-283.
134. Niwa T, Aiuchi T, Nakaya K et al: Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form. Clin Nephrol 1993;39:92-96.
135. Costigan MG, Callaghan CA, Lindup WE: Hypothesis: Is accumulation of a furan dicarboxylic acid (3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure? Nephron 1996;73:169-173.
136. Costigan MG, Yaqoob M, Lindup WE: Retention of an albumin-bound furan dicarboxylic acid in patients with chronic renal failure or after a kidney transplant. Nephrol Dial Transplant 1996;11: 803-807.
137. Niwa T: Organic acids and the uremic syndrome: Protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol 1996;16:167-182.
138. Niwa T, Asada H, Tsutsui S, Miyazaki T: Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis. Am J Nephrol 1995;15:463-467.
139. Perna AF, Ingrosso D, Santo NG, Galletti P, Zappia V: Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995;47:247-253.
140. Clarke R, Daly L, Robinson K et al: Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324:1149-1155.
141. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
142. Tsai JC, Perrella MA, Yoshizumi M et al: Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-6373.
143. Matthias D, Becker CH, Riezler R, Kindling PH: Homocysteine-induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis 1996;122:201-216.
144. Harpel PC, Zhang X, Borth W: Homocysteine and hemostasis: Pathogenic mechanisms predisposingtothrombosis. J Nutr 1996;126:1285S-1289S.
145. Bostom AG, Shemin D, Lapane KL et al: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis 1995;114:93-103.
146. Robinson K, Gupta A, Dennis V et al: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996;94:2743-2748.
147. Oishi K, Nagake Y, Yamasaki H et al: The significance of serum homocysteine levels in diabetic patients on haemodialysis. Nephron Dial Transplant 2000;15:851-855.
148. Suliman ME, Qureshi AR, Barany P et al: Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000;57:1727-1735.
149. Van Guldener C, Janssen MJ, De Meer K, Donker AJ, Stehouwer CD: Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. J Intern Med 1999;245:175-183.
150. Moustapha A, Gupta A, Robinson K et al: Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 1999;55:1470-1475.
151. Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 1993;40: 230-235.
152. Fodinger M, Mannhalter C, Wolfl G et al: Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997;52: 517-523.
153. Van Guldener C, Kulik W, Berger R et al: Homocysteine and methionine metabolism in ESRD: A stable isotope study. Kidney Int 1999;56:1064-1071.
154. Arnadottir M, Berg AL, Hegbrant J, Hultberg B: Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 1999;14:142-146.
155. Vychytil A, Fodinger M, Papagiannopoulos M et al: Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. Kidney Int 1999;55:2054-2061.
156. Brulez HF, van Guldener C, Donker AJ, ter Wee PM: The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant 1999;14:154-159.
157. Ubbink JB, Vermaak WJ, van der MA, Becker PJ: Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993;57:47-53.
158. Bostom AG, Gohh RY, Beaulieu AJ et al: Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med 1997;127:1098-1092.
159. Wilcken DE, Dudman NP, Tyrrell PA, Robertson MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 1988;37:697-701.
160. Suliman ME, Divino Filho JC, Barany P et al: Effects of high-dose folic acid and pyridoxine on plasma and erythrocyte sulfur amino acids in hemodialysis patients. J Am Soc Nephrol 1999;10: 1287-1296.
161. 12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease. Metabolism 1999;48:631-635.
162. Hoffer LJ, Bank I, Hongsprabhas P et al: A tale of two homocysteines - and two hemodialysis units. Metabolism 2000;49:215-219.
163. Touam M, Zingraff J, Jungers P et al: Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int 1999;56:2292-2296.
164. Bostom AG, Shemin D, Bagley P et al: Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation 2000;101:2829-2832.
165. Van Guldener C, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD: Carotid artery stiffness in patients with end-stage renal disease: No effect of long-term homocysteine-lowering therapy. Clin Nephrol 2000;53:33-41.
166. Vanholder R, De Smet R, Gervasio R, Ringoir S: In vivo solute elimination of paired filtration dialysis. Int J Artif Organs 1991;14:23-27.
167. Yu HH, Joubran R, Asmi M et al: Agreement among four homocysteine assays and results in patients with coronary atherosclerosis and controls. Clin Chem 2000;46:258-264.
168. De Smet R, David F, Sandra P et al: A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 1998;278:1-21.
169. Mingrone G, De Smet R, Greco AV et al: Serum uremic toxins from patients with chronic renal failure displace the binding of L-tryptophan to human serum albumin. Clin Chim Acta 1997;260: 27-34.
170. Vanholder R, Hoefliger N, De Smet R, Ringoir S: Extraction of protein bound ligands from azotemic sera: Comparison of 12 deproteinization methods. Kidney Int 1992;41:1707-1712.
171. Marescau B, Deshmukh DR, Kockx M et al: Guanidino compounds in serum, urine, liver, kidney, and brain of man and some ureotelic animals. Metabolism 1992;41:526-532.
172. Marescau B, Nagels G, Possemiers I et al: Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 1997;46:1024-1031.
173. Yu PH, Dyck RF: Impairment of methylamine clearance in uremic patients and its nephropathological implications. Clin Nephrol 1998;49:299-302.
174. Knoflach A, Binswanger U: Serum hippuric acid concentration in renal allograft rejection, ureter obstruction, and tubular necrosis. Transplant Int 1994;7:17-21.
175. Niwa T, Nomura T, Sugiyama S et al: The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 1997;52(suppl 62):S23-S28.
176. Weiss T, Bernhardt G, Buschauer A, Jauch KW, Zirngibl H: High-resolution reversed-phase high-performance liquid chromatography analysis of polyamines and their monoacetyl conjugates by fluorescence detection after derivatization with N-hydroxysuccinimidyl-6-quinolinyl carbamate. Anal Biochem 1997;247:294-304.
177. Suliman ME, Anderstam B, Bergstrom J: Evidence of taurine depletion and accumulation of cysteinesulfinic acid in chronic dialysis patients. Kidney Int 1996;50:1713-1717.
178. Weiss MF, Erhard P, Kader-Attia FA et al: Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 2000;57:2571-2585.
179. Miyata T, Horie K, Ueda Y, et al: Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000;58:425-435.
180. Floridi A, Trizza V, Paolotti P, Lucarelli C: Analytical strategy for the assessment of the protein glycation status in uremic patients by high-performance liquid chromatography. J Chromatogr A 1999;846:65-71.
181. Kaplan AA, Halley SE, Lapkin RA, Graeber CW: Dialysate protein losses with bleach processed polysulphone dialyzers. Kidney Int 1995;47:573-578.
182. Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H: Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 1993;17:809-813.
183. Vanholder R, De Smet R, Lesaffer G: p-Cresol: A toxin revealing many neglected but relevant aspects of uraemic toxicity (editiorial). Nephrol Dial Transplant 1999;14:2813-2815.
184. Mucsi I, Hercz G, Uldall R et al: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998;53:1399-1404.
185. Kooistra MP, Vos J, Koomans HA, Vos PF: Daily home haemodialysis in The Netherlands: Effects on metabolic control, haemodynamics, and quality of life. Nephrol Dial Transplant 1998;13:2853-2860.
186. Fagugli RM, Buoncristiani U, Ciao G: Anemia and blood pressure correction obtained by daily hemodialysis induce a reduction of left ventricular hypertrophy in dialysed patients (letter). Int J Artif Organs 1998;21:429-431.
187. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. J Engl J Med 1993;329:1001-1006.
188. Hida M, Aiba Y, Sawamura S et al: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996;74:349-355.
189. Ling WH, Hanninen O: Shifting from a conventional diet to an uncooked vegan diet reversibly alters fecal hydrolytic activities in humans. J Nutr 1992;122:924-930.
190. Niwa T, Yazawa T, Ise M et al: Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremic rats. Nephron 1991;57:84-88.
191. Niwa T, Miyazaki T, Hashimoto N et al: Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats. Am J Nephrol 1992;12:201-206.
192. Boss GR, Seegmiller JE: Hyperuricemia and gout. Classification, complications and management. N Engl J Med 1979;300:1459-1468.
193. Yokozawa T, Fujioka K, Oura H, Nonaka G, Nishioka I: Effects of rhubarb tannins on uremic toxins. Nephron 1991;58:155-160.
194. Yatzidis H, Koutsicos D, Agroyannis B et al: Biotin in the management of uremic neurologic disorders. Nephron 1984;36:183-186.
195. Shinzato T, Morita H, Maeda K: Metabolism and kinetics of propylurofuranic acid in end-stage renal failure. ASAIO J 1994;40:94-96.
196. Bostom AG, Shemin D, Lapane KL et al: High-dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49:147-152.
197. Morgan SH, Maher ER, Purkiss P, Watts RW, Curtis JR: Oxalate metabolism in end-stage renal disease: The effect of ascorbic acid and pyridoxine. Nephrol Dial Transplant 1988;3:28-32.
198. Raj DS, Choudhury D, Welbourne TC, Levi M: Advanced glycation end products: A nephrologist's perspective. Am J Kidney Dis 2000;35:365-380.
199. Miyata T, Kurokawa K, van Ypersele de Strihou C: Advanced glycation and lipoxidation end products: Role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 2000;11:1744-1752.
200. Rottembourg J: Residual renal function and recovery of renal function in patients treated by CAPD. Kidney Int 1993;43(suppl 40):S106-S110.
201. Motojima M, Nishijima F, Ikoma M et al: Role for 'uremic toxin' in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991;40:461-469.